title: Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice.
abstract: Fas ligand triggers cell death after interaction with its receptor Fas. Altered expression of Fas has been associated with lymphoproliferation and autoimmune disorders in both mice and man. Apoptosis of lung and liver tissue is seen in Fas ligand transgenic mice. It is not known whether constitutive expression of Fas ligand can cause a similar human disease. Four patients with aggressive large granular lymphocyte (LGL) leukaemia involving lung and liver were studied. All four patients were severely ill with pulmonary involvement. Two patients presented with hypoxia and were oxygen dependent; the other two patients had severe pulmonary hypertension. Lung biopsies showed interstitial infiltration by leukaemic LGL. The infiltrating lymphocytes expressed both Fas and Fas ligand, whereas normal pneumocytes expressed only Fas. Similar findings were observed in liver biopsies from these patients. Features mimicking the pathological changes of graft-versus-host disease were observed, including pneumocyte apoptosis. All four patients had high levels of circulating Fas ligand. Successful treatment with oral methotrexate or 2-chlorodeoxyadenosine was associated with disappearance or marked reduction of circulating Fas ligand. These results suggest that dysregulated expression of Fas ligand can lead to human disease with pathological features resembling graft-versus-host disease.
authors.affiliation: H. Lee Moffitt Cancer Center and Research Institute, The Veterans' Administration Hospital, and the Department of Medicine and Microbiology/Immunology, University of South Florida Medical School, Tampa, FL, USA.
authors.forename: T
authors.initials: T
authors.lastname: Lamy
authors.forename: F A
authors.initials: FA
authors.lastname: Bauer
authors.forename: J H
authors.initials: JH
authors.lastname: Liu
authors.forename: Y X
authors.initials: YX
authors.lastname: Li
authors.forename: E
authors.initials: E
authors.lastname: Pillemer
authors.forename: H
authors.initials: H
authors.lastname: Shahidi
authors.forename: S A
authors.initials: SA
authors.lastname: Gregory
authors.forename: R
authors.initials: R
authors.lastname: Zambello
authors.forename: R
authors.initials: R
authors.lastname: Marcolongo
authors.forename: G
authors.initials: G
authors.lastname: Semenzato
authors.forename: T P
authors.initials: TP
authors.lastname: Loughran
mesh_terms: D000328:Adult; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D017209:Apoptosis; D053222:Fas Ligand Protein; D005260:Female; D015870:Gene Expression; D006801:Humans; D016130:Immunophenotyping; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D017254:Leukemic Infiltration; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics*; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D008875:Middle Aged; D019014:fas Receptor / Q000235:genetics*
chemical_list: D000964:Antimetabolites, Antineoplastic; C505661:FASLG protein, human; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008562:Membrane Glycoproteins; D019014:fas Receptor; D008727:Methotrexate